Yes, throat cancer that is positive for the Human Papillomavirus known as HPV responds significantly better to treatment than throat cancer caused by traditional risk factors like smoking and alcohol. In the UK, HPV status is now considered one of the most important prognostic factors for oropharyngeal cancer, which affects the tonsils and the base of the tongue. Patients with HPV positive tumours typically have a much more favourable outlook, with higher survival rates and a better response to standard therapies like radiotherapy and chemotherapy.
The reason for this improved response is biological. HPV positive cancer cells have a built in sensitivity to radiation because the virus interferes with the cells ability to repair DNA damage. When specialists apply radiotherapy, these viral infected cells are less able to recover compared to the more resistant cells found in smoking related cancers. Because of this high sensitivity, the majority of HPV positive cases can be cured even when the cancer has spread to local lymph nodes in the neck.
What we will discuss in this article
- Why HPV positive tumours are more sensitive to radiotherapy
- Survival statistics comparing HPV positive and HPV negative cases
- The role of smoking and alcohol in affecting treatment outcomes
- Why standard cisplatin chemotherapy remains the preferred choice in 2026
- The status of de-escalation trials in the UK for low risk patients
- How HPV status influences the long term monitoring plan
- Clinical differences in how these cancers present in the clinic
Survival rates and treatment response
In the UK, the difference in cure rates between HPV positive and HPV negative throat cancer is stark. Clinical data from organisations like Cancer Research UK shows that the type of virus involved changes the expected outcome dramatically.
- HPV Positive Success: For many patients with HPV related oropharyngeal cancer, the five year survival rate exceeds 80 to 90 percent. When caught early, the cure rate can be as high as 95 percent.
- HPV Negative Outlook: In contrast, throat cancers that are HPV negative: usually those linked to long term tobacco use: have lower five year survival rates, often ranging between 50 and 60 percent.
- Platform Independence: HPV positive tumours respond well regardless of the treatment modality. Whether a patient undergoes primary surgery, radiotherapy, or combined chemoradiotherapy, the response is generally superior to HPV negative counterparts.
The De-Escalate trial and standard of care
- Cisplatin vs Cetuximab: A major UK trial called De-Escalate compared the standard chemotherapy drug cisplatin with a supposedly less toxic drug called cetuximab.
- The Results: The trial found that cisplatin was not only more effective at preventing the cancer from returning but also resulted in better overall survival. Interestingly, cetuximab did not significantly reduce side effects as expected.
- Current Standard: As of 2026, high dose cisplatin combined with radiotherapy remains the gold standard of care in the NHS for all eligible patients with HPV positive throat cancer, as it provides the highest chance of a permanent cure.
Comparison: HPV Positive vs HPV Negative Throat Cancer
| Feature | HPV-Positive Cancer | HPV-Negative Cancer |
| Primary Cause | HPV 16 or 18 virus | Smoking and alcohol use |
| Typical Patient | Younger, non smokers | Older, history of tobacco use |
| Radiation Sensitivity | High: DNA repair is limited | Low: Cells are more resistant |
| 3-Year Survival Rate | Approximately 90 to 93 percent | Approximately 45 to 60 percent |
| Common Location | Tonsils and base of tongue | Larynx and lower throat |
| Nodal Spread | Often presents with neck lumps | Often presents with throat pain |
To Summarise
The identification of HPV as a primary cause of throat cancer has transformed how specialists approach the disease in the UK. HPV positive throat cancer responds exceptionally well to treatment, offering patients a much higher chance of survival compared to traditional smoking related cancers. While the medical community continues to research ways to reduce treatment intensity for these responsive tumours, the current evidence strongly supports the use of standard chemoradiotherapy to maximise cure rates. Understanding your HPV status is a vital part of your diagnosis, as it provides a clear indication that the cancer is highly treatable and that the long term prognosis is excellent.
If you have been diagnosed with an oropharyngeal tumour, ensure that your biopsy has been tested for p16 or HPV DNA to confirm your status and inform your treatment plan.
How is HPV status tested?
Specialists use a marker called p16. If a tumour shows high levels of p16 protein during a biopsy, it is almost always a sign that the cancer is caused by HPV.
Does being HPV positive mean the cancer is easier to treat?
In terms of the tumours sensitivity to medicine and radiation, yes. However, the treatment itself: usually seven weeks of radiotherapy and chemotherapy: is still intensive and requires a high level of supportive care.
Can I still get a good result if I am a smoker with HPV cancer?
Smoking can reduce the effectiveness of treatment even in HPV positive cases. Specialists in the UK strongly advise all patients to stop smoking immediately to give the treatment the best possible chance of working.
Why are HPV positive cancers becoming more common?
While smoking rates have declined, HPV infections have become the leading cause of throat cancer in the UK. This is often due to infections acquired several decades ago that remained dormant before developing into cancer.
Is the HPV vaccine helping?
The UK national vaccination programme for girls and boys is expected to significantly reduce these cancers in the future. However, because throat cancer takes decades to develop, we will not see the full impact on cancer rates until the 2040s.
Will I need more surgery if I am HPV positive?
Often, no. Because HPV positive tumours are so sensitive to chemoradiotherapy, surgery is frequently avoided unless the cancer does not fully clear after the initial treatment.
Authority Snapshot
This article was reviewed by Dr. Stefan Petrov, a UK trained physician with an MBBS and postgraduate certifications including Basic Life Support BLS, Advanced Cardiac Life Support ACLS, and the UK Medical Licensing Assessment PLAB 1 and 2. Dr. Petrov has extensive clinical experience in general medicine, surgery, and emergency care within the NHS. He has managed the diagnostic pathway and care of patients with head and neck malignancies and is well versed in the prognostic significance of HPV status in modern oncology. This guide follows the standard UK clinical pathways and NICE guidelines for the management of oropharyngeal cancer.
